Publicacions en col·laboració amb investigadors/es de University Hospital of Geneva (13)

2024

  1. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

    Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

2022

  1. Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 65-122

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. MHC Class II antigen presentation by lymphatic endothelial cells in tumors promotes intratumoral regulatory T cell-suppressive functions

    Cancer Immunology Research, Vol. 9, Núm. 7, pp. 748-764

2019

  1. Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization

    Molecular Therapy - Methods and Clinical Development, Vol. 15, pp. 403-417

2018

  1. Absence of MHC-II expression by lymph node stromal cells results in autoimmunity

    Life Science Alliance, Vol. 1, Núm. 6

  2. Dendritic cell migration toward CCL21 gradient requires functional Cx43

    Frontiers in Physiology, Vol. 9, Núm. MAR

2017

  1. Pannexin1 links lymphatic function to lipid metabolism and atherosclerosis

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Human hepatocyte-derived induced pluripotent stem cells: MYC expression, similarities to human germ cell tumors, and safety issues

    Stem Cells International, Vol. 2016

  2. PDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation

    Journal of Autoimmunity, Vol. 67, pp. 8-18

2015

  1. Macroautophagy in endogenous processing of self- and pathogen-derived antigens for MHC class II presentation

    Frontiers in Immunology, Vol. 6, Núm. SEP

2014

  1. Ag-presenting CpG-activated pDCs prime Th17 cells that induce tumor regression

    Cancer Research, Vol. 74, Núm. 22, pp. 6430-6440

2004

  1. Anti-inflammatory effects of hepatocyte growth factor: Induction of interleukin-1 receptor antagonist

    European Cytokine Network, Vol. 15, Núm. 4, pp. 303-311